Tesamorelin, CJC-1295, and Ipamorelin Peptide Blend Research


• Research indicates that GH-Secretagogue and ghrelin receptor agonists may be characteristics of the compound Ipamorelin. 

Image: Handout

A chemically manufactured analog of growth hormone-releasing hormone (GHRH), CJC-1295 (no DAC) is a peptide that consists of 29 amino acids and is also known as Modified GRF (1-29).

The molecular structure of this peptide is comparable to that of GHRH (it has substitutions of amino acids at just four locations).

Still, it is distinct from GHRH in that it may maintain its activity in the bloodstream for longer. Studies suggest that increasing growth hormone (GH) and insulin-like growth factor (IGF-1) levels may be possible with CJC-1295, potentially without causing unwelcome responses.

Ipamorelin Peptide: What is it?

Research indicates that GH-Secretagogue and ghrelin receptor agonists may be characteristics of the compound Ipamorelin.

It is possible to draw parallels between the efficacy of ghrelin stimulation and that of GHRP6, which is believed to have fewer appetite-stimulating impacts.

It is important to note that in contrast to other GH-Secretagogues, this pentapeptide does not seem to produce the same quantities of cortisol, acetylcholine, prolactin, or aldosterone. Ipamorelin has been regarded as the first selective GH-Secretagogue because it may have these properties.

Tesamorelin Peptide: What is it?

Investigations purport that the growth hormone-releasing analog known as Tesamorelin may raise insulin-like growth factor-1 (IGF-1) levels in both male and female animal research models.

Findings imply that this growth hormone may bind to and excite the GHRH receptors, which may be comparable to that of GHRH. The extent to which it binds to and activates GHRH receptors is believed to be comparable to endogenous GHRH expression.

Scientists speculate that there may be many other properties, such as the fact that it may lower triglycerides and might have nootropic potential.

Tesamorelin has been theorized to reduce the thickness of the carotid intima-media (cIMT), visceral adipose tissue (VAT), and C-reactive proteins (CRP) in research that was conducted not too long ago. It has not been speculated that it might impact other pituitary hormones or their associated processes. Additionally, it has been asserted to enhance cognitive performance incases of zero to mild cognitive impairment, with elevated risk of Alzheimer's disease development.

CJC-1295, Ipamorelin, and Tesamorelin Peptide Blend: Synergy

Tesamorelin, CJC1295, and Ipamorelin have been suggested to synergistically impact the release of growth hormone when exposed in combination. This suggests that the aggregate impact of their actions might be higher than the sum of their separate impacts. In a coordinated way, the peptides have been reported to stimulate the pituitary gland, increasing the growth hormone secreted.

CJC-1295, Ipamorelin, and Tesamorelin Peptide Blend: Physiological Potential

Studies suggest that the combination may have the potential to elicit elevated amounts of growth hormone, which may result in a variety of physiological outcomes. Growth hormone is believed to regulate metabolism, promote tissue repair and regeneration, and determine the organism's composition. Research indicates that Tesamorelin, CJC-1295, and Ipamorelin Blend may help improve these areas since they may increase the release of growth hormones.

CJC-1295, Ipamorelin, and Tesamorelin Peptide Blend: Growth Hormone

Through its proposed direct interaction with the GHRH receptor, Tesamorelin has been hypothesized to induce growth hormone production. Increasing the pulsatile release of growth hormone and extending the half-life of endogenous GHRH are both believed to be possible impacts of CJC1295. Ipamorelin is believed to be responsible for stimulating the pituitary gland's growth hormone release by activating certain receptors in the gland. Investigations purport that the release of growth hormones may increase due to the combined impacts of these peptides.

CJC-1295, Ipamorelin, and Tesamorelin Peptide Blend: Summary

Findings imply that given that Tesamorelin & CJC-1295 & Ipamorelin may stimulate GHRH, it is common practice to combine these three compounds to get more favorable research outcomes. Ipamorelin has been suggested to have several useful impacts, including a faster rate of fat reduction, enhanced sleep cycle regulation, higher energy levels, and long-term synthesis of growth hormone. This becomes more clear when CJC-1295 is included in the blend. As a result of the sustained increase in growth hormone (hGH) synthesis that occurs after a cycle, the organism is theorized to maintain the properties for a longer period than the original concentration.

Tesamorelin has been speculated as an additional property to enhance the organism's structure as a whole. Because the synthesis of growth hormone (GH) normally decreases over time, this peptide is believed to have the potential in practical research, as it may help to enhance the production of GH. Physical activity is also thought to benefit growth hormone secretion (GH). In addition to being the most adaptable growth hormone-releasing peptide, this particular peptide is also the least aggressive. It is claimed to be the most appropriate peptide since, unlike other peptides, it does not appear to induce unwelcome ancillary physiological action.

Research has indicated that the blend of the three peptides may increase the production of growth hormone (GH) and levels of insulin-like growth factor-1 (IGF-1), as well as bone density, cognitive function and memory, cellular repair and regeneration, fat loss, and other potential actions.


[i] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P. and Frohman, L. A. (2006) 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults', J Clin Endocrinol Metab,91(3), pp. 799-805.

[ii] Sackmann-Sala, L., Ding, J., Frohman, L. A. and Kopchick, J. J. (2009) 'Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects', Growth Horm IGF Res,19(6), pp. 471-7.

[iii] Onescu, M. and Frohman, L. A. (2006) 'Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog', J Clin Endocrinol Metab,91(12), pp. 4792-7.

[iv] Rahman, F., McLaughlin, T. A., Mesquita, P., Morin, J., Potvin, D., de Chantal, M., & Aberg, J. (2022). Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Cambridge Core. https://dx.doi.org/10.1017/cts.2022.515

[v] Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the Detection of Growth Hormone Releasing Hormone Synthetic Analogs. Wiley Online Library. https://dx.doi.org/10.1002/dta.3183

Check out the latest news here and you are welcome to join our super exclusive Mpasho WhatsApp group for all the latest and breaking news in entertainment. We would also like to hear from you, WhatsApp us on +254 736 944935.